Literature DB >> 10486178

Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.

H Takashima1, M Tsujihata, M Kishikawa, W J Freed.   

Abstract

Neuroprotective properties of bromocriptine, a D(2) receptor agonist, were investigated using the in vitro neurotoxicity of levodopa for dopaminergic neurons from rat embryonic ventral mesencephalon. Levodopa, when added to the culture medium, showed toxicity which was specific for dopaminergic neurons. Bromocriptine was found to protect dopaminergic neurons from levodopa toxicity. Another D(2) agonist, 2-(N-phenethyl-N-propyl-amino-5-hydroxytetralin, showed similar protective effects. The neuroprotective effect of bromocriptine was inhibited by supplementation of the culture medium with sulpiride, a D(2) antagonist, or by D(2) receptor knockdown with an antisense oligonucleotide. Dopaminergic neurons treated with levodopa showed an increase in free radicals. These data suggest that neuroprotective properties of bromocriptine seen in this cellular model of neurotoxicity are dependent on dopamine D(2) autoreceptor binding and that levodopa toxicity may be related to increased free radical generation in dopaminergic neurons. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486178     DOI: 10.1006/exnr.1999.7122

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  15 in total

1.  Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.

Authors:  Venugopalan D Nair; C Warren Olanow; Stuart C Sealfon
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  Role of renal DJ-1 in the pathogenesis of hypertension associated with increased reactive oxygen species production.

Authors:  Santiago Cuevas; Yanrong Zhang; Yu Yang; Crisanto Escano; Laureano Asico; John E Jones; Ines Armando; Pedro A Jose
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

Review 3.  Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Authors:  W D Le; J Jankovic
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.

Authors:  G Gille; K Radad; H Reichmann; W-D Rausch
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

5.  The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death.

Authors:  K Ishige; Q Chen; Y Sagara; D Schubert
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

6.  D1 Antagonists and D2 Agonists Have Opposite Effects on the Metabolism of Dopamine in the Rat Striatum.

Authors:  Alberto Avila-Luna; Jacqueline Prieto-Leyva; Arturo Gálvez-Rosas; Alfonso Alfaro-Rodriguez; Rigoberto Gonzalez-Pina; Antonio Bueno-Nava
Journal:  Neurochem Res       Date:  2015-05-17       Impact factor: 3.996

Review 7.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture.

Authors:  Lyle Wiemerslage; Bradley J Schultz; Archan Ganguly; Daewoo Lee
Journal:  J Neurochem       Date:  2013-03-24       Impact factor: 5.372

9.  Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.

Authors:  Giulia Ferrari-Toninelli; Giuseppina Maccarinelli; Daniela Uberti; Erich Buerger; Maurizio Memo
Journal:  BMC Pharmacol       Date:  2010-02-05

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.